$NKTX earnings report

Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update. AlphAI read Nkarta's Third Quarter 2026 filing as mixed.

Third Quarter 2026

AlphAI · Earnings readNKTX · Third Quarter 2026 · ended September 30, 2026

Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update

→Mixed quarter

Nkarta reported continued NKX019 clinical-program execution and cash expected to fund its operating plan into 2029, while third-quarter R&D expense, total operating expense and net loss were higher than the prior-year quarter.

EPS · GAAP
$ (0.45 )

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expense, three months ended September 30, 2026GAAP$29.46M––
Non-cash stock-based compensation included in R&D expense, third quarter of 2026GAAP$700K––
General and administrative expense, three months ended September 30, 2026GAAP$6.31M––
Non-cash stock-based compensation included in G&A expense, third quarter of 2026GAAP$1.1M––
Total operating expenses, three months ended September 30, 2026GAAP$35.78M––
Loss from operations, three months ended September 30, 2026GAAP−$35.78M––
Interest income, three months ended September 30, 2026GAAP$2.25M––
Other income, net, three months ended September 30, 2026GAAP$206K––
Total other income, net, three months ended September 30, 2026GAAP$2.45M––
Net loss, three months ended September 30, 2026GAAP−$33.33M––
Net loss per share, basic and diluted, three months ended September 30, 2026GAAP$ (0.45 )––
Weighted average shares used to compute net loss per share, basic and diluted, three months ended September 30, 2026GAAP74,637,689––
Research and development expense, nine months ended September 30, 2026GAAP$83.50M––
General and administrative expense, nine months ended September 30, 2026GAAP$26.28M––
Total operating expenses, nine months ended September 30, 2026GAAP$109.8M––
Loss from operations, nine months ended September 30, 2026GAAP−$109.8M––
Interest income, nine months ended September 30, 2026GAAP$7.62M––
Other income, net, nine months ended September 30, 2026GAAP$634K––
Total other income, net, nine months ended September 30, 2026GAAP$8.26M––
Net loss, nine months ended September 30, 2026GAAP−$101.5M––
Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP$ (1.36 )––
Weighted average shares used to compute net loss per share, basic and diluted, nine months ended September 30, 2026GAAP74,464,897––
Non-cash charges included in net loss, third quarter of 2026GAAP$2.8M––
Cash, cash equivalents, restricted cash and investments, September 30, 2026GAAP$216.0M––
Property and equipment, net, September 30, 2026GAAP$54.59M––
Operating lease right-of-use assets, September 30, 2026GAAP$30.5M––
Other assets, September 30, 2026GAAP$7.34M––
Total assets, September 30, 2026GAAP$308.5M––
Accounts payable, accrued and other liabilities, September 30, 2026GAAP$20.68M––
Operating lease liabilities, September 30, 2026GAAP$72.04M––
Total liabilities, September 30, 2026GAAP$92.71M––
Stockholders' equity, September 30, 2026GAAP$215.7M––
Total liabilities and stockholders' equity, September 30, 2026GAAP$308.5M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Current operating plan outlook

  • NoteNkarta expects its current cash and cash equivalents to fund its current operating plan into 2029.

What drove it

  • Initial clinical data from the Ntrust program in idiopathic inflammatory myopathy and systemic sclerosis are scheduled for presentation at ACR Convergence 2026.
  • Enrollment continues in the multi-center, open-label, dose-escalation Ntrust program.
  • Outpatient dosing is underway within a network of community-based sites.
  • Patients are being dosed at 4 billion cells per dose x 3 doses (12 billion cells total) across all indications in Ntrust-1 and Ntrust-2.

Concerns

  • Net loss was $ (33,326 ) (in thousands) for the three months ended September 30, 2026, versus $ (21,715 ) (in thousands) for the prior-year period.
  • R&D expense was $ 29,464 (in thousands) for the three months ended September 30, 2026, versus $ 20,198 (in thousands) for the prior-year period.
  • The company stated that initial, interim or preliminary clinical data may reflect a limited number of patients with limited follow-up and may change as additional data become available.
  • Nkarta has no products approved for sale, according to the forward-looking-statement risk discussion.

What to watch

  • The oral presentation in myositis on November 8 at ACR Convergence 2026.
  • The systemic sclerosis poster on November 9 at ACR Convergence 2026.
  • The oral presentation of safety data across autoimmune indications on November 11 at ACR Convergence 2026.
  • Continued enrollment and outpatient dosing in Ntrust-1 and Ntrust-2.
  • Execution against the stated expectation that current cash and cash equivalents will fund the current operating plan into 2029.

Balance sheet and cash flow

  • Cash, cash equivalents, restricted cash and investments were $216.0 million as of September 30, 2026.
  • Cash, cash equivalents, restricted cash and investments: $ 216,026 (in thousands) at September 30, 2026; $ 295,129 (in thousands) at December 31, 2025.
  • Total assets: $ 308,461 (in thousands) at September 30, 2026; $ 404,209 (in thousands) at December 31, 2025.
  • Total liabilities: $ 92,712 (in thousands) at September 30, 2026; $ 91,884 (in thousands) at December 31, 2025.
  • Operating lease liabilities: $ 72,037 (in thousands) at September 30, 2026; $ 76,420 (in thousands) at December 31, 2025.
  • Stockholders' equity: $ 215,749 (in thousands) at September 30, 2026; $ 312,325 (in thousands) at December 31, 2025.

Analysis

Nkarta's third-quarter update was centered on clinical execution for NKX019 rather than commercial activity. The company said enrollment continues in Ntrust-1 and Ntrust-2, with outpatient dosing underway at community-based sites. Patients are being dosed at 4 billion cells per dose x 3 doses (12 billion cells total) across all indications in the two trials. The filing did not report revenue or operating segments.

The near-term clinical catalyst is ACR Convergence 2026. Nkarta plans an oral myositis presentation on November 8, a systemic sclerosis poster on November 9, and an oral safety presentation across autoimmune indications on November 11. These presentations concern initial clinical data from the Ntrust program in the company's lead indications of idiopathic inflammatory myopathy and systemic sclerosis.

Operating spending increased versus the prior-year quarter. R&D expense was $ 29,464 (in thousands), compared with $ 20,198 (in thousands), and total operating expenses were $ 35,777 (in thousands), compared with $ 27,286 (in thousands). G&A expense was $ 6,313 (in thousands), compared with $ 7,088 (in thousands). Net loss was $ (33,326 ) (in thousands), or $ (0.45 ), compared with $ (21,715 ) (in thousands), or $ (0.29 ). Interest income was $ 2,245 (in thousands), below $ 3,852 (in thousands) in the prior-year quarter.

Liquidity remains the principal financial support for the development plan. Cash, cash equivalents, restricted cash and investments were $ 216,026 (in thousands) at September 30, 2026, compared with $ 295,129 (in thousands) at December 31, 2025. Nkarta expects its current cash and cash equivalents to fund its current operating plan into 2029. No operating cash flow, free cash flow, share repurchases, dividends, revenue guidance, expense guidance, or tax-rate guidance was reported.

Management, verbatim

NKX019 is advancing in our two lead indications, myositis and systemic sclerosis.

Paul J. Hastings, Chief Executive Officer of Nkarta

We’re delighted to have been selected to present our initial clinical data in two oral presentations and one poster presentation at ACR Convergence 2026 in Orlando.

Paul J. Hastings, Chief Executive Officer of Nkarta

We believe that the safety profile of engineered CAR-NK cells could broaden cell therapy access to reach far more patients.

Paul J. Hastings, Chief Executive Officer of Nkarta

Not in the filing

stated, not guessed
  • Revenue and revenue comparisons were not reported.
  • Gross profit and gross margin were not reported.
  • Operating cash flow, free cash flow and a cash-flow statement were not reported.
  • Non-GAAP financial metrics were not reported.
  • Segment revenue and segment profitability were not reported.
  • Share repurchases, dividends and other capital-return activity were not reported.
  • Prior-quarter comparisons were not reported for the financial-statement line items.
  • Revenue, gross-margin, operating-expense and tax-rate numerical guidance were not reported.
  • A prior outlook section was not provided, so no comparison with prior guidance is available.
  • Debt other than operating lease liabilities was not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about NKTX earnings dates

When is Nkarta's next earnings date?
AlphAI has no date for NKTX yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.